Good review practices: The first step forward for the Korea food and drug administration

Drug Information Journal

Volumn 39, Issue 2, 2005, Pages 185-192

  Lee, Howard ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical review; Clinical trial regulations, Korea Food and Drug Administration; Good Clinical Practices; Good Review Practices; Review template; Third party review; U.S. Food and Drug Administration

Indexed keywords

CLINICAL PRACTICE; FOOD AND DRUG ADMINISTRATION; KOREA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; UNITED STATES;

EID: 18444392118     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150503900209     Document Type: Review

References (29)

1. Lee H, Kim C, Shin SG. Changes in clinical trial practice and the working environment in the Korean pharmaceutical industry since the implementation of Good Clinical Practice. Drug Inf J. 2001;35:203-210.
2. Lee H, KW Lim, JH Park. A survey of industrial perspectives on the Central Pharmaceutical Affairs Council's review of clinical trial protocols and study reports. Kor J Clin Pharmacol Ther. 1998;6(1):11-28.
3. The Korea Food and Drug Administration needs more experts for the drug review and approval process. The Yakup Daily. Feb 27, 2003.
4. The quality of the review process. (editorial) Reg Aff J. 2000;913-916.
5. International Conference on Harmonisation. E6: Good Clinical Practice Consolidated Guideline (Step 4). Geneva, Switzerland: International Conference on Harmonisation; 1996.
6. The quality of the review process: Industry and regulators deliberate. CMR Int News. 2001;18:22-24.
7. Smith ND. Good Review Practices. Presented at the DIA Meeting Progress in Clinical Trials, February 14, 2004, Tokyo, Japan.
8. th Annual Meeting, July 10, 2001, Denver, CO.
9. Lesko LJ, Williams R. The Question-Based Review, A conceptual framework for Good Review Practices. Appl Clin Trials. 1999;8(6):56-62.
10. U.S. Food and Drug Administration Task Force on Risk Management. Managing the Risks from Medical Product Use - Creating a Risk Management Framework. Rockville, MD: U.S. Food and Drug Administration Task Force on Risk Management; 1999.
11. Kessler DA. Remarks by David A. Kessler, M.D., at the Food Drug and Law Institute Annual Meeting. Available at: http://www.fda.gov/bbs/topics/SPEECH/ SPE00062.htm. Accessed September 17, 2004.
12. The U.S. Congress. The Prescription Drug User Fee Act of 1992.1992.
13. The U.S. Congress. The Prescription Drug User Fee Act of 1997. 1997.
14. The U.S. Congress. The Prescription Drug User Fee Amendments of 2002 In: The Public Health Security and Bioterrorism Preparedness and Response Act of 2002. 2002.
15. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Reviewer Guidance (Draft). Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review. Rockville, MD: U.S. Food and Drug Administration, Center for Drug Evaluation and Research; 1996.
16. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Reviewers. Pharmacology/Toxicology Review Format. Rockville, MD: U.S. Food and Drug Administration, Center for Drug Evaluation and Research; 2001.
17. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Procedures for Assessments Performed by the Quality Assurance Staff. Manual of Policies and Procedures: Center for Drug Evaluation and Research. MAPP 4112.4. Rockville, MD: U.S. Food and Drug Administration, Center for Drug Evaluation and Research; 2004.
18. th Annual Meeting, July 10, 2001, Denver, CO.
19. th Annual Meeting, July 10, 2001, Denver, CO.
20. rd Soyang Conference, August 20, 2004, Chuncheon, Korea.
21. Organizational Chart. The Korea Food and Drug Administration. Available at: http://www.Korean Food and Drug Administration.go.kr/cgi-bin/t4.cgi/eng/ english_04.taf . 4-11-2004. Accesed September 17, 2004.
22. Kim SY. To become a strong biopharmaceutical nation. The JoongAng Daily. July 16, 2001.
23. Jeon MS. If Korea Food and Drug Administration does not reform itself, Korea will be left out of the Asian clinical trial markets within three years. Interview with Prof. Sang-Goo Shin. Korean Pharma J. March 29, 2004.
24. Yoo TM. Introduction to organization and job description: The Department of Drug Evaluation. Presented at the Public Forum for New Drug Review Procedures by the Korean Food and Drug Administration, Seoul, Korea, March 18, 2004.
25. Jeon MH. Korea Food and Drug Administration to facilitate and streamline drug review processes. More information will be made publicly available. The Daily Pharma. March 19, 2004.
26. Lee DH, Nam SY. Clinical trial systems in developed countries. Korean J Pharma Med. 2004;2(1): 10-17.
27. The Center for Drug Evaluation. Available at: http://www.cde.org.tw/ english/english.htm. Accessed September 17, 2004.
28. Center for Devices and Radiological Health, The Food and Drug Administration. Third-Party Review. Available at: http://www.fda.gov/cdrh/ thirdparty/. Accessed September 17, 2004.
29. Kim CJ. Development of clinical trials - why it is necessary and how it can be achieved. J Korean Med Assoc. 2003;46(12):1064-1069.